Form 10-K APPLIED GENETIC TECHNOLO For: Jun 30

Go back to Form 10-K APPLIED GENETIC TECHNOLO For: Jun 30

Roth Reaffirms Applied Genetic (AGTC) at 'Buy' Following FY15 Results; Fundamental Thesis Remains Unchanged

September 11, 2015 8:29 AM EDT

Roth Capital reaffirms its Buy rating and $34 price target on Applied Genetic Technologies (Nasdaq: AGTC) following Q4, FY15 results reported Thursday night.

Analyst Joseph Pantginis noted that AGTC reported FY15 loss of $1.50 per share, versus the firm's loss expectation of $1.37 per share.

Pantginis commented, We believe... More

Applied Genetic Technologies (AGTC) Posts Q4 Loss of 48c/Share

September 11, 2015 7:28 AM EDT

Applied Genetic Technologies (NASDAQ: AGTC) reported Q4 EPS of ($0.48), $0.07 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $713 thousand versus the consensus estimate of $630 thousand.

For earnings history and earnings-related data on Applied Genetic Technologies (AGTC) click here.

... More